These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 9467959

  • 21. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 22. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.
    Br J Haematol; 2008 Jan 15; 140(2):181-90. PubMed ID: 18028486
    [Abstract] [Full Text] [Related]

  • 23. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 24. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr 14; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 25. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
    Haematologica; 2003 Jun 14; 88(6):622-30. PubMed ID: 12801837
    [Abstract] [Full Text] [Related]

  • 26. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.
    Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF.
    Oncogene; 1996 Nov 21; 13(10):2225-34. PubMed ID: 8950990
    [Abstract] [Full Text] [Related]

  • 27. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
    Barnes DJ, Schultheis B, Adedeji S, Melo JV.
    Oncogene; 2005 Sep 22; 24(42):6432-40. PubMed ID: 16007188
    [Abstract] [Full Text] [Related]

  • 28. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 29. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ, Chen HC, Peng XH.
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec 28; 25(6):570-2. PubMed ID: 12516408
    [Abstract] [Full Text] [Related]

  • 30. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
    Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ.
    Oncogene; 2001 May 10; 20(21):2636-46. PubMed ID: 11420675
    [Abstract] [Full Text] [Related]

  • 31. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H.
    Clin Cancer Res; 1998 Jul 10; 4(7):1661-72. PubMed ID: 9676840
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
    Hariharan IK, Adams JM, Cory S.
    Oncogene Res; 1988 Jul 10; 3(4):387-99. PubMed ID: 3147434
    [Abstract] [Full Text] [Related]

  • 34. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
    Evans CA, Owen-Lynch PJ, Whetton AD, Dive C.
    Cancer Res; 1993 Apr 15; 53(8):1735-8. PubMed ID: 8467488
    [Abstract] [Full Text] [Related]

  • 35. BCR/ABL confers growth factor independence upon a murine myeloid cell line.
    Mandanas RA, Boswell HS, Lu L, Leibowitz D.
    Leukemia; 1992 Aug 15; 6(8):796-800. PubMed ID: 1379313
    [Abstract] [Full Text] [Related]

  • 36. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.
    Issaad C, Ahmed M, Novault S, Bonnet ML, Bennardo T, Varet B, Vainchenker W, Turhan AG.
    Leukemia; 2000 Apr 15; 14(4):662-70. PubMed ID: 10764152
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines.
    Zhu J, Nabissa PM, Hoffman B, Liebermann DA, Shore SK.
    Blood; 1996 May 15; 87(10):4368-75. PubMed ID: 8639797
    [Abstract] [Full Text] [Related]

  • 39. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.
    Kabarowski JH, Allen PB, Wiedemann LM.
    EMBO J; 1994 Dec 15; 13(24):5887-95. PubMed ID: 7813429
    [Abstract] [Full Text] [Related]

  • 40. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion.
    Anderson SM, Mladenovic J.
    Blood; 1996 Jan 01; 87(1):238-44. PubMed ID: 8547647
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.